Year None202620252024202320222021 March 27, 2026 Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update January 6, 2026 Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
March 27, 2026 Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
January 6, 2026 Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco